TANVI VIJAY GUJARAN^1,#, VIGNESH BALAJI EASWARAN^1,#, RUNALI SANKHE¹, PUGAZHANDHI BAKTHAVATCHALAM^2,3, HERMAN SUNIL DSOUZA⁴, K. SREEDHARA RANGANATH PAI^1,*

Oncology Research, Vol.33, No.2, pp. 381-395, 2025, DOI:10.32604/or.2024.049538 - 16 January 2025

Abstract Background: To date, there is no effective cure for the highly malignant brain tumor glioblastoma (GBM). GBM is the most common, aggressive central nervous system tumor (CNS). It commonly originates in glial cells such as microglia, oligodendroglia, astrocytes, or subpopulations of cancer stem cells (CSCs). Glucose plays an important role in the, which energy metabolism of normal and cancer cells, but cancer cells exhibit an increased demand for glucose is required for their differentiation and proliferation. The main aim of this study is to explore the anti-cancer efficacy of the ketogenic diet against GBM. Also,… More >

ZAREMA GILAZIEVA¹, DANIIL MOLDAVSKII¹, EKATERINA LUZINA¹, AISYLU KADYROVA¹, ALISA SHAIMARDANOVA¹, SHAZA ISSA², ALBERT RIZVANOV^1,3,*, VALERIYA SOLOVYEVA¹

BIOCELL, Vol.48, No.12, pp. 1667-1681, 2024, DOI:10.32604/biocell.2024.058490 - 30 December 2024

Abstract Aggressive malignant brain tumors have a poor prognosis, and early detection can significantly improve treatment effectiveness and increase patient survival rates. Various methods are available for diagnosing brain tumors, with biopsy being one of the primary options. However, a biopsy is an invasive procedure that carries a risk of brain damage, highlighting the need for safer alternatives. One promising non-invasive method is liquid biopsy, which involves extracting extracellular vesicles (EVs) from different biological fluids. Most cell types can produce and release extracellular vesicles. EVs isolated from bodily fluids, along with the molecules they carry—such More >

MAHDI ABDOLI SHADBAD¹, BEHZAD BARADARAN^2,*

Oncology Research, Vol.32, No.12, pp. 1949-1958, 2024, DOI:10.32604/or.2024.051569 - 13 November 2024

Abstract Background: Glioblastoma remains a highly invasive primary brain malignancy with an undesirable prognosis. Growing evidence has shed light on the importance of microRNAs (miRs), as small non-coding RNAs, in tumor development and progression. The present study leverages the in-silico and in-vitro techniques to investigate the significance of hsa-miR-181a-5p and the underlying hsa-miR-181a-5p-meidated signaling pathway in glioblastoma development. Methods: Bioinformatic studies were performed on GSE158284, GSE108474 (REMBRANDT study), TCGA-GTEx, CCLE, GeneMANIA, Reactome, WikiPathways, KEGG, miRDB, and microT-CDS to identify the significance of hsa-miR-181a-5p and its underlying target. Afterward, the U373 cell line was selected and transfected with… More >

JI SHI^1,2, YE ZHANG², YI CHEN², TANGJUN GUO^3,*, HAOZHE PIAO^2,*

BIOCELL, Vol.48, No.8, pp. 1241-1263, 2024, DOI:10.32604/biocell.2024.051049 - 02 August 2024

Abstract Background: Glioblastoma multiforme (GBM) is the most general malignancy of the primary central nervous system that is characterized by high aggressiveness and lethality. Transmembrane protein 159 (TMEM159) is an endoplasmic reticulum protein that can form oligomers with seipin. The TMEM159-seipin complex decides the site of lipid droplet (LD) formation, and the formation of LDs is a marker of GBM. However, the role of TMEM159 in the progression of GBM has not been investigated to date. Methods: In this study, we examined the genes that may be associated with patient prognosis in GBM by bioinformatics analyses,… More >

DIMITRA P. VAGELI^1,2,*, PANAGIOTIS G. DOUKAS³, KERASIA GOUPOU², ANTONIOS D. BENOS², KYRIAKI ASTARA^2,4, KONSTANTINA ZACHAROULI², SOTIRIS SOTIRIOU⁵, MARIA IOANNOU²

Oncology Research, Vol.32, No.8, pp. 1239-1256, 2024, DOI:10.32604/or.2024.052130 - 17 July 2024

Abstract Glioblastoma multiforme (GBM) is an aggressive primary brain tumor characterized by extensive heterogeneity and vascular proliferation. Hypoxic conditions in the tissue microenvironment are considered a pivotal player leading tumor progression. Specifically, hypoxia is known to activate inducible factors, such as hypoxia-inducible factor 1alpha (HIF-1α), which in turn can stimulate tumor neo-angiogenesis through activation of various downward mediators, such as the vascular endothelial growth factor (VEGF). Here, we aimed to explore the role of HIF-1α/VEGF immunophenotypes alone and in combination with other prognostic markers or clinical and image analysis data, as potential biomarkers of GBM prognosis… More >

LAN ZHOU^1,#, QI ZHANG^2,#, BO TIAN^1,*, FENG YANG^1,*

BIOCELL, Vol.48, No.7, pp. 1081-1093, 2024, DOI:10.32604/biocell.2024.049878 - 03 July 2024

Abstract Background: Glioblastoma, a notably malignant tumor within the central nervous system, is distinguished by its aggressive behavior. Silvestrol, a robust inhibitor of the RNA helicase eukaryotic initiation factor 4A (eIF4A), has shown significant potential as an anticancer compound. Yet, the impact of silvestrol on glioblastoma, especially its molecular mechanisms, has not been fully elucidated. Methods: This investigation employed a variety of in vitro assays, such as cell counting kit-8 (CCK-8), clonogenic, 5-ethynyl-2′-deoxyuridine (EDU), wound healing, and flow cytometry, to evaluate cell cycle progression, apoptosis, cell viability, and migration. Western blot analysis was also performed to study… More >

ZHAOYING ZHU^1,#, YANJIA HU^2,#, FENG YE², HAIBO TENG², GUOLIANG YOU¹, YUNHUI ZENG², MENG TIAN², JIANGUO XU², JIN LI², ZHIYONG LIU², HAO LIU^2,*, NIANDONG ZHENG^1,*

Oncology Research, Vol.32, No.7, pp. 1173-1184, 2024, DOI:10.32604/or.2024.042456 - 20 June 2024

Abstract Background: Inhibitor of NF-κB kinase-interacting protein (IKIP) is known to promote proliferation of glioblastoma (GBM) cells, but how it affects migration and invasion by those cells is unclear. Methods: We compared levels of IKIP between glioma tissues and normal brain tissue in clinical samples and public databases. We examined the effects of IKIP overexpression and knockdown on the migration and invasion of GBM using transwell and wound healing assays, and we compared the transcriptomes under these different conditions to identify the molecular mechanisms involved. Results: Based on data from our clinical samples and from public databases, More >

MAHER KURDI^1,*, ALAA ALKHOTANI², ABDULRAHMAN SABBAGH³, EYAD FAIZO⁴, AHMED I. LARY⁵, AHMED K. BAMAGA⁶, MAJID ALMANSOURI⁷, BADR HAFIZ⁸, THAMER ALSHARIF⁹, SALEH BAEESA⁸

Oncology Research, Vol.32, No.6, pp. 1037-1045, 2024, DOI:10.32604/or.2024.051112 - 23 May 2024

Abstract Background: The dysregulation of Isocitrate dehydrogenase (IDH) and the subsequent production of 2-Hydroxyglutrate (2HG) may alter the expression of epigenetic proteins in Grade 4 astrocytoma. The interplay mechanism between IDH, O-6-methylguanine-DNA methyltransferase (MGMT)-promoter methylation, and protein methyltransferase proteins-5 (PRMT5) activity, with tumor progression has never been described. Methods: A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors. Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis. Inter-cohort statistical significance was evaluated. Results: Both IDH-mutant WHO grade 4 astrocytomas (n = 22, 64.7%) and IDH-wildtype… More > Graphic Abstract

KARAN WADHWA¹, PAYAL CHAUHAN¹, SHOBHIT KUMAR², RAKESH PAHWA^3,*, RAVINDER VERMA⁴, RAJAT GOYAL⁵, GOVIND SINGH¹, ARCHANA SHARMA⁶, NEHA RAO³, DEEPAK KAUSHIK^1,*

Oncology Research, Vol.32, No.5, pp. 877-897, 2024, DOI:10.32604/or.2024.047278 - 23 April 2024

Abstract Background: Glioblastoma multiforme (GBM) is recognized as the most lethal and most highly invasive tumor. The high likelihood of treatment failure arises from the presence of the blood-brain barrier (BBB) and stem cells around GBM, which avert the entry of chemotherapeutic drugs into the tumor mass. Objective: Recently, several researchers have designed novel nanocarrier systems like liposomes, dendrimers, metallic nanoparticles, nanodiamonds, and nanorobot approaches, allowing drugs to infiltrate the BBB more efficiently, opening up innovative avenues to prevail over therapy problems and radiation therapy. Methods: Relevant literature for this manuscript has been collected from a comprehensive More > Graphic Abstract

NILAM BHUSARE, MAUSHMI KUMAR^*

Oncology Research, Vol.32, No.5, pp. 849-875, 2024, DOI:10.32604/or.2024.047042 - 23 April 2024

Abstract Glioblastoma, the most aggressive form of brain tumor, poses significant challenges in terms of treatment success and patient survival. Current treatment modalities for glioblastoma include radiation therapy, surgical intervention, and chemotherapy. Unfortunately, the median survival rate remains dishearteningly low at 12–15 months. One of the major obstacles in treating glioblastoma is the recurrence of tumors, making chemotherapy the primary approach for secondary glioma patients. However, the efficacy of drugs is hampered by the presence of the blood-brain barrier and multidrug resistance mechanisms. Consequently, considerable research efforts have been directed toward understanding the underlying signaling pathways… More > Graphic Abstract